$FATE
Fate Therapeutics Inc

2022 Q1 Form 10-Q Financial Statement

#000095017022007389 Filed on May 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $18.41M $11.14M
YoY Change 65.27% 343.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.74M $12.50M
YoY Change 65.94% 61.71%
% of Gross Profit
Research & Development $72.14M $44.85M
YoY Change 60.84% 53.19%
% of Gross Profit
Depreciation & Amortization $2.761M $959.0K
YoY Change 187.9% 36.03%
% of Gross Profit
Operating Expenses $92.88M $57.35M
YoY Change 61.95% 54.98%
Operating Profit -$74.47M -$46.21M
YoY Change 61.15% 33.97%
Interest Expense $8.777M $1.120M
YoY Change 683.66% 15.46%
% of Operating Profit
Other Income/Expense, Net $8.777M $1.121M
YoY Change 682.96% 15.33%
Pretax Income -$65.69M -$45.09M
YoY Change 45.69% 34.52%
Income Tax
% Of Pretax Income
Net Earnings -$65.69M -$45.09M
YoY Change 45.69% 34.51%
Net Earnings / Revenue -356.74% -404.68%
Basic Earnings Per Share -$0.68
Diluted Earnings Per Share -$681.8K -$482.6K
COMMON SHARES
Basic Shares Outstanding 96.43M 93.78M
Diluted Shares Outstanding 96.34M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $573.8M $790.1M
YoY Change -27.38% 288.64%
Cash & Equivalents $64.74M $106.4M
Short-Term Investments $509.0M $683.7M
Other Short-Term Assets $11.45M $7.200M
YoY Change 59.07% 44.0%
Inventory
Prepaid Expenses
Receivables $13.85M $6.900M
Other Receivables $0.00 $0.00
Total Short-Term Assets $599.1M $804.3M
YoY Change -25.52% 286.22%
LONG-TERM ASSETS
Property, Plant & Equipment $97.86M $115.2M
YoY Change -15.05% 868.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.94M $98.30M
YoY Change -30.88% 510.56%
Other Assets $33.00K $15.20M
YoY Change -99.78% 168788.89%
Total Long-Term Assets $259.3M $241.7M
YoY Change 7.29% 112.69%
TOTAL ASSETS
Total Short-Term Assets $599.1M $804.3M
Total Long-Term Assets $259.3M $241.7M
Total Assets $858.4M $1.046B
YoY Change -17.94% 224.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.44M $9.000M
YoY Change 27.16% 73.98%
Accrued Expenses $35.11M $20.93M
YoY Change 67.74% 77.83%
Deferred Revenue $22.58M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $77.91M $94.60M
YoY Change -17.64% 279.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $147.1M $161.3M
YoY Change -8.81% 107.59%
Total Long-Term Liabilities $147.1M $161.3M
YoY Change -8.81% 107.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $77.91M $94.60M
Total Long-Term Liabilities $147.1M $161.3M
Total Liabilities $225.0M $255.9M
YoY Change -12.08% 149.17%
SHAREHOLDERS EQUITY
Retained Earnings -$834.8M
YoY Change
Common Stock $97.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $633.4M $790.1M
YoY Change
Total Liabilities & Shareholders Equity $858.4M $1.046B
YoY Change -17.94% 224.96%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$65.69M -$45.09M
YoY Change 45.69% 34.51%
Depreciation, Depletion And Amortization $2.761M $959.0K
YoY Change 187.9% 36.03%
Cash From Operating Activities -$64.61M -$27.10M
YoY Change 138.46% 1.59%
INVESTING ACTIVITIES
Capital Expenditures $10.08M $3.981M
YoY Change 153.3% 272.06%
Acquisitions
YoY Change
Other Investing Activities $3.058M -$467.9M
YoY Change -100.65% -1983.7%
Cash From Investing Activities -$7.026M -$471.9M
YoY Change -98.51% -2084.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.797M 438.1M
YoY Change -99.36% 30089.52%
NET CHANGE
Cash From Operating Activities -64.61M -27.10M
Cash From Investing Activities -7.026M -471.9M
Cash From Financing Activities 2.797M 438.1M
Net Change In Cash -68.84M -60.93M
YoY Change 12.98% 4108.15%
FREE CASH FLOW
Cash From Operating Activities -$64.61M -$27.10M
Capital Expenditures $10.08M $3.981M
Free Cash Flow -$74.70M -$31.08M
YoY Change 140.36% 12.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 fate Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001434316
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36076
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
FATE THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-1311552
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12278 Scripps Summit Drive
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
875-1800
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
FATE
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96629085
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64741000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133583000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13850000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8676000
CY2022Q1 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
509031000
CY2021Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
482327000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11453000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8826000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
599075000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
633412000
CY2022Q1 us-gaap Long Term Investments
LongTermInvestments
67942000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
100664000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
97857000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91529000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
69475000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70720000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2022Q1 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
8777000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
529907000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
135224000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
62000000
CY2021Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
9870000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2022Q1 us-gaap Assets
Assets
858386000
CY2021Q4 us-gaap Assets
Assets
921455000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
11444000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8612000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35110000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42412000
CY2022Q1 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2021Q4 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22575000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21483000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5582000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5577000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
77911000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81284000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22534000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27124000
CY2022Q1 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2021Q4 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107939000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
109241000
CY2022Q1 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
15809000
CY2021Q4 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
24168000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96538084
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96538084
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95726962
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95726962
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
97000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1470916000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1448584000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2850000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-762000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-834773000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-769083000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
633393000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
858386000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
921455000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18414000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11142000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72139000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44852000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20742000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12500000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
92881000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
57352000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-74467000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46210000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
418000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
377000
CY2022Q1 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-8359000
CY2021Q1 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-744000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8777000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1121000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-65690000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-45089000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2088000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-330000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-67778000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-45419000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96343529
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
93431877
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-65690000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-45089000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2761000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
959000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19331000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12976000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-873000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1140000
CY2022Q1 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1094000
CY2021Q1 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
623000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3497000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3107000
CY2022Q1 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-8359000
CY2021Q1 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-744000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5174000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7026000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-471888000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2797000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5605000
CY2021Q1 fate Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
432445000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1430000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2407000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1301000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3493000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6944000
CY2022Q1 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-52000
CY2021Q1 fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
1933000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64613000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27096000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10084000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3981000
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
132166000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60934000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148810000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2797000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
438050000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68842000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182574000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79968000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121640000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3377000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2624000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1444000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, accrued expenses, stock-based compensation, and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64741000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106413000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79968000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121640000
CY2022Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2021Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-65700000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27700000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-45100000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25500000
CY2022Q1 fate Expected Ressarch Services Period
ExpectedRessarchServicesPeriod
P4Y
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
763000
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020 fate Period To Treat Award As Grant If Award Not Treated As Loan
PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan
P10Y
CY2021 fate Investment Maturity Date Range
InvestmentMaturityDateRange
1 or les
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
443799000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2864000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
414126000
CY2022Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2022Q1 us-gaap Share Price
SharePrice
38.77
CY2022Q1 us-gaap Share Price
SharePrice
38.77
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 fate Fair Value Liabilities Level1 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel3TransfersAmount
0
CY2022Q1 fate Fair Value Liabilities Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel2ToLevel3TransfersAmount
0
CY2022Q1 fate Fair Value Liabilities Level3 To Level2 Transfers Amount
FairValueLiabilitiesLevel3ToLevel2TransfersAmount
0
CY2022Q1 fate Fair Value Liabilities Level3 To Level1 Transfers Amount
FairValueLiabilitiesLevel3ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
11568000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
18358000
CY2022Q1 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
10511000
CY2021Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
12344000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13031000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11710000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35110000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42412000
CY2022Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y1M6D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.069
CY2022Q1 fate Straight Line Lease Expense
StraightLineLeaseExpense
3815000
CY2021Q1 fate Straight Line Lease Expense
StraightLineLeaseExpense
3534000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
618000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
235000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4433000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3769000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11285000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14498000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14836000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15087000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
15540000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
16006000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
101636000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
188888000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
75367000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
113521000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12976000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19331000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3001000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19331000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2088000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-65690000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
633393000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
384445000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5648000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12976000
CY2021Q1 fate Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
432445000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-330000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-45089000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
790095000

Files In Submission

Name View Source Status
0000950170-22-007389-index-headers.html Edgar Link pending
0000950170-22-007389-index.html Edgar Link pending
0000950170-22-007389.txt Edgar Link pending
0000950170-22-007389-xbrl.zip Edgar Link pending
fate-20220331.htm Edgar Link pending
fate-20220331.xsd Edgar Link pending
fate-20220331_cal.xml Edgar Link unprocessable
fate-20220331_def.xml Edgar Link unprocessable
fate-20220331_htm.xml Edgar Link completed
fate-20220331_lab.xml Edgar Link unprocessable
fate-20220331_pre.xml Edgar Link unprocessable
fate-ex31_1.htm Edgar Link pending
fate-ex31_2.htm Edgar Link pending
fate-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending